VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $36,342,011 | +19.6% | 712,868 | +17.2% | 0.01% | +11.1% |
| Q2 2023 | $30,386,992 | +66.3% | 608,470 | +24.8% | 0.01% | +50.0% |
| Q1 2023 | $18,276,485 | -22.0% | 487,633 | -0.2% | 0.01% | -25.0% |
| Q4 2022 | $23,422,568 | +182.7% | 488,479 | +41.5% | 0.01% | +166.7% |
| Q3 2022 | $8,286,000 | +31.5% | 345,226 | +19.2% | 0.00% | +50.0% |
| Q2 2022 | $6,303,000 | -0.5% | 289,647 | +10.4% | 0.00% | 0.0% |
| Q1 2022 | $6,335,000 | +9.9% | 262,291 | +8.2% | 0.00% | 0.0% |
| Q4 2021 | $5,765,000 | -4.4% | 242,319 | +1.9% | 0.00% | 0.0% |
| Q3 2021 | $6,032,000 | +55.2% | 237,748 | +37.7% | 0.00% | +100.0% |
| Q2 2021 | $3,886,000 | +44.5% | 172,603 | +26.7% | 0.00% | 0.0% |
| Q1 2021 | $2,690,000 | -13.9% | 136,178 | +15.8% | 0.00% | 0.0% |
| Q4 2020 | $3,125,000 | -45.5% | 117,593 | +1.3% | 0.00% | -66.7% |
| Q3 2020 | $5,732,000 | – | 116,065 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |